{"pmid":32445288,"title":"Challenges and strategies to research ethics in conducting COVID-19 research.","text":["Challenges and strategies to research ethics in conducting COVID-19 research.","The number of research involving human subjects on coronavirus disease 2019 (COVID-19) is surging, bringing challenges to the ethical review committee (ERC) in terms of reviewing speed and special ethical considerations under the pandemic. However, the existing ethical review system and regulations have their limitations to meet the demand for a prompt and efficient epidemic control. Since the research under the public health emergency is different from that carried out in familiar situations to design and implementation, the strategy for a satisfactory ERC response should balance the duty of protecting individual participants as well as the special public needs derived from the disease control. It is suggested that the ethical review-related regulations need to be updated, and a unified supervision system to the overall ERC is required. ERC collaboration, capacity-improving and efficiency-improving measures need to be taken. With respect to the reviewing guidelines, it is suggested that the international norms should be explained with more consideration of the local condition and the exceptional circumstances in this public health emergency. A joint effort needs to be taken for better research conduction.","J Evid Based Med","Ma, Xitao","Wang, Yanqiao","Gao, Tian","He, Qing","He, Yan","Yue, Rensong","You, Fengming","Tang, Jianyuan","32445288"],"abstract":["The number of research involving human subjects on coronavirus disease 2019 (COVID-19) is surging, bringing challenges to the ethical review committee (ERC) in terms of reviewing speed and special ethical considerations under the pandemic. However, the existing ethical review system and regulations have their limitations to meet the demand for a prompt and efficient epidemic control. Since the research under the public health emergency is different from that carried out in familiar situations to design and implementation, the strategy for a satisfactory ERC response should balance the duty of protecting individual participants as well as the special public needs derived from the disease control. It is suggested that the ethical review-related regulations need to be updated, and a unified supervision system to the overall ERC is required. ERC collaboration, capacity-improving and efficiency-improving measures need to be taken. With respect to the reviewing guidelines, it is suggested that the international norms should be explained with more consideration of the local condition and the exceptional circumstances in this public health emergency. A joint effort needs to be taken for better research conduction."],"journal":"J Evid Based Med","authors":["Ma, Xitao","Wang, Yanqiao","Gao, Tian","He, Qing","He, Yan","Yue, Rensong","You, Fengming","Tang, Jianyuan"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445288","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jebm.12388","keywords":["covid-19","ethical review","informed consent","public health emergency"],"weight":0,"_version_":1667600475913977856,"score":9.490897,"similar":[{"pmid":32219845,"title":"Responding to Covid-19: How to Navigate a Public Health Emergency Legally and Ethically.","text":["Responding to Covid-19: How to Navigate a Public Health Emergency Legally and Ethically.","Few novel or emerging infectious diseases have posed such vital ethical challenges so quickly and dramatically as the novel coronavirus SARS-CoV-2. The World Health Organization declared a public health emergency of international concern and recently classified Covid-19 as a worldwide pandemic. As of this writing, the epidemic has not yet peaked in the United States, but community transmission is widespread. President Trump declared a national emergency as fifty governors declared state emergencies. In the coming weeks, hospitals will become overrun, stretched to their capacities. When the health system becomes stretched beyond capacity, how can we ethically allocate scarce health goods and services? How can we ensure that marginalized populations can access the care they need? What ethical duties do we owe to vulnerable people separated from their families and communities? And how do we ethically and legally balance public health with civil liberties?","Hastings Cent Rep","Gostin, Lawrence O","Friedman, Eric A","Wetter, Sarah A","32219845"],"abstract":["Few novel or emerging infectious diseases have posed such vital ethical challenges so quickly and dramatically as the novel coronavirus SARS-CoV-2. The World Health Organization declared a public health emergency of international concern and recently classified Covid-19 as a worldwide pandemic. As of this writing, the epidemic has not yet peaked in the United States, but community transmission is widespread. President Trump declared a national emergency as fifty governors declared state emergencies. In the coming weeks, hospitals will become overrun, stretched to their capacities. When the health system becomes stretched beyond capacity, how can we ethically allocate scarce health goods and services? How can we ensure that marginalized populations can access the care they need? What ethical duties do we owe to vulnerable people separated from their families and communities? And how do we ethically and legally balance public health with civil liberties?"],"journal":"Hastings Cent Rep","authors":["Gostin, Lawrence O","Friedman, Eric A","Wetter, Sarah A"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219845","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1002/hast.1090","keywords":["covid-19","allocation of scarce resources","civil liberties","crisis standards of care","novel coronavirus sars-cov-2","public health emergency","public health ethics"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138492297543680,"score":253.47588},{"pmid":32469074,"title":"Paying Participants in COVID-19 Trials.","text":["Paying Participants in COVID-19 Trials.","A variety of trials are in development and underway to examine potential interventions for the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). How should we think about offering payment to participants in these trials? Payment for research participation is ethically contentious even under ideal circumstances, and pandemics are far from ideal. Here, we review the three functions of research payment-reimbursement, compensation, and incentive-and identify heightened and novel ethical concerns in the context of a global pandemic. We argue that COVID-19 trial participants should usually be offered reimbursement for research-related expenses, as well as compensation for their time and effort, as is true for other types of research under usual circumstances. Given increased risk of undue influence against pandemic background conditions, incentive payment should be avoided unless essential to recruitment and retention in important trials whose social value outweighs this risk. Where essential, however, incentives can be ethically permissible, so long as reasonable efforts are made to minimize the possibility of undue influence.","J Infect Dis","Largent, Emily A","Lynch, Holly Fernandez","32469074"],"abstract":["A variety of trials are in development and underway to examine potential interventions for the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). How should we think about offering payment to participants in these trials? Payment for research participation is ethically contentious even under ideal circumstances, and pandemics are far from ideal. Here, we review the three functions of research payment-reimbursement, compensation, and incentive-and identify heightened and novel ethical concerns in the context of a global pandemic. We argue that COVID-19 trial participants should usually be offered reimbursement for research-related expenses, as well as compensation for their time and effort, as is true for other types of research under usual circumstances. Given increased risk of undue influence against pandemic background conditions, incentive payment should be avoided unless essential to recruitment and retention in important trials whose social value outweighs this risk. Where essential, however, incentives can be ethically permissible, so long as reasonable efforts are made to minimize the possibility of undue influence."],"journal":"J Infect Dis","authors":["Largent, Emily A","Lynch, Holly Fernandez"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469074","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/infdis/jiaa284","keywords":["covid","informed consent","payment","research ethics","undue influence"],"weight":0,"_version_":1668167109945851905,"score":242.0794},{"pmid":32250281,"pmcid":"PMC7141248","title":"Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","text":["Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support.","JMIR Public Health Surveill","Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P","32250281"],"abstract":["As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support."],"journal":"JMIR Public Health Surveill","authors":["Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250281","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.2196/18887","keywords":["covid-19","clinical research","ethics","infectious disease","outbreak","pandemic","public health"],"weight":0,"_version_":1666138491030863872,"score":240.42343},{"pmid":32479747,"title":"COVID-19 human challenge studies: ethical issues.","text":["COVID-19 human challenge studies: ethical issues.","COVID-19 poses an extraordinary threat to global public health and an effective vaccine could provide a key means of overcoming this crisis. Human challenge studies involve the intentional infection of research participants and can accelerate or improve vaccine development by rapidly providing estimates of vaccine safety and efficacy. Human challenge studies of low virulence coronaviruses have been done in the past and human challenge studies with severe acute respiratory syndrome coronavirus 2 have been proposed. These studies of coronaviruses could provide considerable benefits to public health; for instance, by improving and accelerating vaccine development. However, human challenge studies of severe acute respiratory syndrome coronavirus 2 in particular might be controversial, in part, for ethical reasons. The ethical issues raised by such studies thus warrant early consideration involving, for example, broad consultation with the community. This Personal View provides preliminary analyses of relevant ethical considerations regarding human challenge studies of severe acute respiratory syndrome coronavirus 2, including the potential benefits to public health and to participants, the risks and uncertainty for participants, and the third-party risks (ie, to research staff and the wider community). We argue that these human challenge studies can reasonably be considered ethically acceptable insofar as such studies are accepted internationally and by the communities in which they are done, can realistically be expected to accelerate or improve vaccine development, have considerable potential to directly benefit participants, are designed to limit and minimise risks to participants, and are done with strict infection control measures to limit and reduce third-party risks.","Lancet Infect Dis","Jamrozik, Euzebiusz","Selgelid, Michael J","32479747"],"abstract":["COVID-19 poses an extraordinary threat to global public health and an effective vaccine could provide a key means of overcoming this crisis. Human challenge studies involve the intentional infection of research participants and can accelerate or improve vaccine development by rapidly providing estimates of vaccine safety and efficacy. Human challenge studies of low virulence coronaviruses have been done in the past and human challenge studies with severe acute respiratory syndrome coronavirus 2 have been proposed. These studies of coronaviruses could provide considerable benefits to public health; for instance, by improving and accelerating vaccine development. However, human challenge studies of severe acute respiratory syndrome coronavirus 2 in particular might be controversial, in part, for ethical reasons. The ethical issues raised by such studies thus warrant early consideration involving, for example, broad consultation with the community. This Personal View provides preliminary analyses of relevant ethical considerations regarding human challenge studies of severe acute respiratory syndrome coronavirus 2, including the potential benefits to public health and to participants, the risks and uncertainty for participants, and the third-party risks (ie, to research staff and the wider community). We argue that these human challenge studies can reasonably be considered ethically acceptable insofar as such studies are accepted internationally and by the communities in which they are done, can realistically be expected to accelerate or improve vaccine development, have considerable potential to directly benefit participants, are designed to limit and minimise risks to participants, and are done with strict infection control measures to limit and reduce third-party risks."],"journal":"Lancet Infect Dis","authors":["Jamrozik, Euzebiusz","Selgelid, Michael J"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479747","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/S1473-3099(20)30438-2","weight":0,"_version_":1668437834940284928,"score":228.87732},{"pmid":32461245,"title":"Ethical guidelines for deliberately infecting volunteers with COVID-19.","text":["Ethical guidelines for deliberately infecting volunteers with COVID-19.","Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made.","J Med Ethics","Richards, Adair D","32461245"],"abstract":["Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made."],"journal":"J Med Ethics","authors":["Richards, Adair D"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461245","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1136/medethics-2020-106322","keywords":["ethics committees/consultation","informed consent","policy guidelines/inst","public policy","research ethics","review boards/review cttes"],"weight":0,"_version_":1668079521316732928,"score":224.42564}]}